Repetitive Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder
Stimulation magnétique transcrânienne répétitive Dans le Traitement Des Troubles Obsessionnels Compulsifs
| Sponsors |
Lead Sponsor: University Hospital, Grenoble |
|---|---|
| Source | University Hospital, Grenoble |
| Brief Summary | Evaluate the therapeutic effect of a functional Magnetic Resonance Imaging (fMRI)-guided and robotized neuronavigated theta burst Transcranial Magnetic Stimulation (TMS) targeting right inferior frontal region in resistant obsessive compulsive disorder (OCD) in a double-blind, randomized, placebo-controlled, monocentric study. |
| Detailed Description | This study evaluates the therapeutic effect of a fMRI-guided and robotized neuronavigated theta burst Transcranial Magnetic Stimulation (TMS) targeting right inferior frontal region in resistant obsessive compulsive disorder (OCD) in a double-blind, randomized, placebo-controlled, monocentric study. The study will also assess the interest of some clinical, neuropsychological, neuroimaging, electrophysiological variables in response prediction, besides physiopathological information. There is an increasing interest in developping treatments for resistant OCD, which are not responding to the conventional treatment, represented by pharmacotherapy associated to cognitive behavioral therapy. Repetitive TMS represents a promising non invasive brain stimulation approach, but efficacy, best available brain target, optimal responder profile and stimulation parameters need to be further documented. In this study, the included patients will be randomly assigned to an active (theta burst TMS) or sham-placebo treatment group. TMS will be added to their stable pharmacotherapy. The brain target, the right inferior frontal region, involved in the inhibition control brain network, will be defined in a personalized manner via a fMRI paradigm for each patient. TMS will be delivered daily for 2 successive weeks. Measures of different clinical, neuropsychological , electrophysiological (cortical excitability) variables will be performed at baseline, as well as at the end of the TMS course, and 1 week after. Other assessments are planned at 3 and 6 months, in order to highlight the evolution of the potential benefit. |
||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Status | Recruiting | ||||||||||||||||||||||||
| Start Date | 2015-05-01 | ||||||||||||||||||||||||
| Completion Date | 2021-05-01 | ||||||||||||||||||||||||
| Primary Completion Date | 2019-11-01 | ||||||||||||||||||||||||
| Phase | N/A | ||||||||||||||||||||||||
| Study Type | Interventional | ||||||||||||||||||||||||
| Primary Outcome |
|
||||||||||||||||||||||||
| Secondary Outcome |
|
||||||||||||||||||||||||
| Enrollment | 56 |
| Condition | |
|---|---|
| Intervention |
Intervention Type: Device Intervention Name: Active Repetitive Transcranial Magnetic Stimulation Description: modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot Arm Group Label: active Transcranial Magnetic Stimulation Intervention Type: Device Intervention Name: Placebo Repetitive Transcranial Magnetic Stimulation Description: Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation. Arm Group Label: Placebo |
| Eligibility |
Criteria:
Inclusion Criteria: - Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR) criteria and validated by an experimented clinician following instruments like SCID (Structured Clinical Interview for DSM IV) or MINI (Mini-International Neuropsychiatric Interview) - with or without associated tics ("Gilles de la Tourette" Syndrome) - Age > 18 years old - Y-BOCS score > 20 and CGI (Clinical Global Impression Scale) score ≥ 4 - Resistant patients to standard treatments - where treatment resistance is defined by partial but insufficient response (Global Assessment of Functioning score GAF score < 60 and/or reduction of Yale Brown Obsessions and Compulsion Scale score < 35%) or lack of response to previous well conducted treatment including: - pharmacotherapy : optimal tolerated dose and adequate duration (> 12 weeks) of at least 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors, clomipramine), and one augmentation strategy (adjunction of an antipsychotic - such as risperidone or olanzapine or aripiprazole - or lithium or buspirone) ; - psychotherapy (at least 6 months of cognitive and behavioral therapy) Exclusion Criteria: - other primary diagnosis than OCD (comorbid tics and depression are tolerated) - comorbid diagnosis of schizophrenia/ psychotic disorder, bipolar disorder, substance abuse or dependance - medical condition involving cognitive decline and affecting brain structures such as Parkinson disease, dementia, multiple sclerosis, HIV (human immunodeficiency virus) infection, lupus etc. - Magnetic Resonance Imaging exclusion criteria (ferromagnetic implants etc) - common TMS exclusion criteria (neurological condition with an increased risk of seizure, cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, intracranial implants (e.g. cochlear implants, electrodes, aneurysm clips, stimulators... ) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed will be excluded - Current use of any investigational drug - pregnancy / breast feeding patients - visual or auditive important deficit Gender: All Minimum Age: 18 Years Maximum Age: N/A Healthy Volunteers: No |
| Overall Official |
|
||||||
|---|---|---|---|---|---|---|---|
| Overall Contact |
Last Name: Mircea POLOSAN, Professor Email: [email protected] |
||||||
| Location |
|
| Location Countries |
France |
|---|---|
| Verification Date |
2020-05-01 |
| Responsible Party |
Type: Sponsor |
| Keywords | |
| Has Expanded Access | No |
| Condition Browse | |
| Number Of Arms | 2 |
| Arm Group |
Label: active Transcranial Magnetic Stimulation Type: Active Comparator Description: Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot Label: Placebo Type: Placebo Comparator Description: Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot |
| Acronym | MAGTOC |
| Study Design Info |
Allocation: Randomized Intervention Model: Parallel Assignment Primary Purpose: Treatment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.